Literature DB >> 3103774

Syringe driver in terminal care.

S B Dover.   

Abstract

Continuous subcutaneous infusions of drugs by syringe driver are used often and successfully in the terminal care of patients when drugs cannot be given orally. Diamorphine is the opioid of choice because of its high solubility. If other drugs such as antiemetics, anticholinergics, sedatives, or steroids are required they may also be given by syringe driver. This method is particularly useful for domiciliary care, where the practical difficulties of providing regular parenteral analgesia are otherwise formidable.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103774      PMCID: PMC1245587          DOI: 10.1136/bmj.294.6571.553

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  19 in total

1.  The myth of haloperidol potentiation.

Authors:  G W Hanks; P J Thomas; T Trueman; E Weeks
Journal:  Lancet       Date:  1983-08-27       Impact factor: 79.321

2.  Continuous subcutaneous analgesics and antiemetics in domiciliary terminal care.

Authors:  H T Hutchinson; G D Leedham; A M Knight
Journal:  Lancet       Date:  1981-12-05       Impact factor: 79.321

3.  Continuous subcutaneous infusion of morphine for the pain of terminal malignancy.

Authors:  C F Campbell; J B Mason; J M Weiler
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

4.  Intensive iron-chelation in thalassaemia.

Authors:  C B Pignatti; P De Stefano
Journal:  Br Med J       Date:  1978-11-18

5.  Restorative proctocolectomy with ileal reservoir: a pathophysiological assessment.

Authors:  R J Nicholls; P Belliveau; M Neill; M Wilks; S Tabaqchali
Journal:  Gut       Date:  1981-06       Impact factor: 23.059

6.  Rectal, bladder and sexual function after mucosal proctectomy with and without a pelvic reservoir for colitis and polyposis.

Authors:  D E Neal; N S Williams; D Johnston
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

7.  Pain and the portable syringe pump.

Authors:  C Regnard; A Newbury
Journal:  Nurs Times       Date:  1983 Jun 29-Jul 5

8.  Slow drug infusions using a portable syringe driver.

Authors:  B M Wright; K Callan
Journal:  Br Med J       Date:  1979-09-08

9.  Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium.

Authors:  U G Ahlfors; P C Baastrup; S J Dencker; K Elgen; O Lingjaerde; V Pedersen; M Schou; O Aaskoven
Journal:  Acta Psychiatr Scand       Date:  1981-09       Impact factor: 6.392

10.  Continuous subcutaneous infusion of morphine in children with cancer.

Authors:  A W Miser; D M Davis; C S Hughes; A F Mulne; J S Miser
Journal:  Am J Dis Child       Date:  1983-04
View more
  7 in total

1.  Comparison of Teflon cannulas and metal needles for subcutaneous infusion in terminal care: a pilot study.

Authors:  M S Youssef; R E Atkinson
Journal:  BMJ       Date:  1990-03-31

2.  Changes in prescribing for terminal care patients in general practice, hospital and hospice over a five-year period.

Authors:  W D Rees
Journal:  J R Coll Gen Pract       Date:  1987-11

Review 3.  Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care.

Authors: 
Journal:  BMJ       Date:  1996-03-30

Review 4.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

5.  Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients.

Authors:  R S Miller; G M Peterson; F Abbott; I Maddocks; D Parker; S McLean
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

6.  [Pharmacotherapy of cancer pain : 2. Use of opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1995-01       Impact factor: 1.107

7.  Morphine and alternative opioids in cancer pain: the EAPC recommendations.

Authors:  G W Hanks; F Conno; N Cherny; M Hanna; E Kalso; H J McQuay; S Mercadante; J Meynadier; P Poulain; C Ripamonti; L Radbruch; J R Casas; J Sawe; R G Twycross; V Ventafridda
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.